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Abstract Prediction and prevention of glaucoma. Neuro-
degenerative eye disease glaucoma is the second leading
cause of blindness with estimated 67 million patients world-
wide. Molecular pathomechanisms of glaucoma demonstrate
both a considerable overlap with and remarkable particu-
larities compared to other neurodegenerative disorders e.g.
Alzheimer’s disease. Identification of pathology-specific
biomarker-sets is essential to develop advanced diagnostic
approaches and personalised patients’ treatment. Subcellular
imaging and expression patterns in blood as the reliable
platform for early/predictive glaucoma diagnosis. Following
key pathways are affected in glaucoma pathology: stress
response, apoptosis and DNA-repair, adhesion, blood-brain-
barrier-breakdown, tissue remodelling, transcription regula-
tion, multidrug resistance and energy metabolism.
Keywords Personalised medicine . Glaucoma . Blood
biomarkers . Specific molecular-profiles . Early/predictive
diagnosis . Targeted preventive measures
Particularities of the neurodegenerative
disease glaucoma
Glaucoma is complex neurodegenerative disease the molec-
ular pathomechanisms of which demonstrate both a con-
siderable overlap and remarkable particularities compared to
some other neurodegenerative disorders such as Alzheimer’s
disease. As an example, neuronal thread protein (NTP)
demonstrates enhanced expression levels in glaucoma
patients against controls [1], the same observation occurred
also for Down Syndrome, Alzheimer’s and some other
diseases [2], indicating axonal lesions as the common feature
but giving no information about the corresponding aetiology.
Simultaneous monitoring of expressional rates of further
TAU-protein enables distinction between the pathologies: in
contrast to the accumulation of TAU-protein characteristic
for Alzheimer’s disease and other tauopathies, glaucoma
patients demonstrate no increase in the target protein
expression versus controls [3]. Therefore, the selection of
biomarkers specifically affected by glaucoma pathology is
of high value creating advanced diagnostic approaches and
targeted prevention and individualised treatment.
Glaucoma is a neurodegenerative eye disease and—
worldwide—the second leading cause of permanent vision
loss with estimated 67 million patients worldwide [4].
Glaucomatous optic neuropathy (GON) is characterised by
a combination of a loss of retinal ganglion cells and their
axons with disease typical optic nerve head (ONH) atrophy
(see Fig. 1). An extensive tissue remodelling accompanying
GON is very complex and the molecular pathomechanisms
of GON are not yet completely clear.
The aetiology of glaucoma and risk factors are only
partially known [6, 7], (see Fig. 2).
IOP (intraocular pressure) is considered the most impor-
tant and only modifiable risk factor in glaucoma. Although
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elevated IOP has been shown to be the major risk factor,
there is a cohort of patients even at younger ages with normal
IOP developing normal-tension glaucoma (NTG) (Fig. 3).
The frequency and incidence of different glaucoma forms
vary geographically, depending on race, sex and age [8–10].
A family history of the disease is common among glaucoma
patients, suggesting a genetic background for this disorder.
The existence of a genetic linkage associated with particular
forms of glaucoma is well documented in literature [10–17].
The growing body of evidence suggests the idea that genetic-
based approaches in early diagnosis of glaucoma and targeted
treatment might yield better results than medical, surgical,
and rehabilitation interventions alone [17]. Although muta-
tion research in glaucoma detected some attractive potential
targets, the mutated genes found—like TIGR—play a limited
role in the pathogenesis of glaucoma and do not explain the
usual clinical picture [9, 18–22]. Therefore, pharmaco-
genetic approaches, if any, would provide only minor success
in prediction of glaucoma.
Are there any molecular diagnostic approaches developed
to preselect glaucoma-predisposed individuals, to distinguish
between glaucoma forms and to estimate a disease progres-
sion?We should state a current lack of clinical approaches for
early and predictive diagnostics of glaucoma. However,
much effort made and recent progress achieved in the
identification of disease characteristic molecular patterns
should be clearly acknowledged—the issue which is
reviewed in this chapter.
Impact of vascular component and relevance of gene
expression patterns in blood for glaucoma pathology
A wealth of literature points to the potential importance of
haemodynamics in glaucoma pathology, but randomised
controlled trials are not yet available. Healthy individuals
with Vasospastic Syndrome demonstrate molecular profiles
in blood similar to those of glaucoma patients [23]. Particular
predisposition of vasospastic individuals to glaucoma is
discussed in the separate review of this journal-issue [24].
Although animal models for glaucoma provided us with
useful information about affected molecular pathways and
potential targets in the eye, they are barely applicable for
non-invasive diagnostics on human being. Since blood is
easily accessible, its molecular analysis, in reasonable
amounts (few millilitres), may prove practical application
in population screening for high-risk subjects. How relevant
are gene expression patterns in blood serum and white blood
cells for the eye? Glaucoma patients frequently exhibit













Fig. 3 Although increased IOP is a well-known risk factor, the IOP
values of normal-tension glaucoma patients are within statistical norm
KNOWN RISK FACTORS: 
- IOP 
- race  
- female gender 
- genetics 
- myopia 
- corneal thickness 
- optic disc haemorrhages 
- haemodynamics, others 
Fig. 2 Risk factors in glaucoma and measurement of intraocular
pressure (IOP) [5]
Fig. 1 Characteristic degenerative tissue remodelling by glaucomatous damage [5]
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antibodies to retina and optic nerve proteins; these alterations
in the cellular subset indicate that the immune system plays
an important role in the initiation and/or progression of
glaucomatous optic neuropathy [25]. Therefore, serum anti-
bodies to retina and optic nerve proteins might be con-
sidered as potential indicators for the diagnosis of glaucoma
pathology [26]. In addition, it has been demonstrated that
gene expression patterns of both trabecular meshwork and
Schlemm´s canal are similar to those of circulating
leucocytes (CL) [27]. Moreover, blood serum is the biggest
reservoir of signalling molecules in human beings: many
metabolites are simultaneously secreted from different types
of cells in blood that represents a universal way of
communication between cells. Although this communication
is extremely complex, one of the known natural sensors
affected by the tremendous number of metabolites present in
blood serum is CL. The spectrum of the molecules affecting
expression patterns in CL is very broad and partially
unknown; their regulation is extremely complex and not yet
completely understood. However, it is known that the
resulting regulation of CL is triggered by altered gene
expression patterns on the levels of transcription and
translation. The resulting shift in a gene expression pattern
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Fig. 4 Protein expression
patterns characteristic for circu-
lating leucocytes of glaucoma
patients [30]. a. 2D-PAGE
images of differential gene
expression patterns in
circulating leucocytes of
glaucoma patients versus con-
trols with particular changes
marked. b. The scheme repre-
sents summarised results from
the evaluation of comparative
2D-PAGE images. 132 protein
spots were constantly present in
all control images, whereby
75 spots were expressed at the
same level. 133 protein spots
were constantly present in
patient images, whereby
52 spots were expressed at the
same level. 17 proteins represent
the overlap between 75 and 52
protein spots. Thirty spots were
present only in the control group
whereas 14 spots were present
only in the patient group; all
spots were detectable only in
single images and, therefore,
were not included in the above
133 and 132 pools. c. Quantita-
tive analysis of 2D-PAGE
images: among 75 and
52 conserved protein spots in
the control and patient groups,
respectively, 17 overlapping
protein spots were found to be
conserved for members of the
same group. Corresponding
expression levels in the control
group are taken as standard (=1).
9 proteins have been identified
as given in the table
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can be measured on both levels. Both vascular and immune
components may play a role in pathomechanisms of
glaucoma [28]. Taking the above into consideration, the
search for disease specific gene expression patterns in
glaucoma is of great value for a better understanding of
the molecular pathomechanisms and creation of predictive
approaches in glaucoma diagnostics.
Key molecular pathways affected by glaucoma
pathology: development of predictive
diagnostic strategies
Keymolecular pathways affected by glaucoma pathology have
been recently summarised in the book specifically dedicated to
predictive diagnostics and personalised treatment [29].
The majority of molecules altered in glaucoma belong to
well-defined functional gene-groups which, altogether,
represent molecular pathways affected by the pathology
(see Fig. 4).
Stress response, apoptosis and DNA-repair
An increased oxidative stress has been well documented
under glaucoma pathology. Many oxidatively modified
proteins were demonstrated in retinal protein lysates from
ocular hypertensive eyes of rat-model of glaucoma [31].
Consequently, altered gene expression patterns, particularly
for stress response factors, can be expected. Thus, the
alteration of heat shock 27 kDa protein 1 expression was
stable in the retina of rat hypertensive eyes [32]. “Gene
hunting” technology of “Subtractive Hybridisation” fol-
lowed by quantification of target transcripts (see Fig. 5)
performed in CL of glaucoma patients revealed an up-
regulation of both the pro-apoptotic factor p53 and
proteolytic enzyme 20S proteasome subunit XAPC7 [1],
activity of which is usually increased during reperfusion
[33]. In agreement with this, both an apoptotic inhibitor
survivin and DNA-repair Xeroderma pigmentosum gene C
have been found to be down-regulated in CL of glaucoma
patients [1]. Moreover, ex vivo subcellular imaging by
“Comet Assay”-analysis demonstrates significantly in-
creased (un-repaired) DNA-damage in circulating leuco-




Gene expression profiles characteristic for an activated
adherent function have been identified in CL of glaucoma
patients: up-regulated transcripts of lymphocyte-IgE-receptor
(Fc-epsilon-RII/CD23), T cell-specific tyrosine kinase (ITK),
thromboxan-A2-receptor, and alkaline-phosphatase have been
detected by “subtractive hybridisation” [36]. Adherent circu-
lating leucocytes (CL) could be an important contributor to
BBB-breakdown observed in glaucoma pathology [37]. The
subtraction of metalloproteinase MMP-9 and MT1-MMP
transcripts highly increased in CL of glaucoma patients
provides further evidence for this functional link and indicates
pathways involved in the extensive tissue remodelling
observed in glaucoma [38]. Significantly increased protein
expression rates of both latent and active forms of MMP-9
and MT1-MMP in CL correlated well with the enhanced
levels of transcription and with glaucoma [38]. Once
activated, both hydrolases necessarily contribute to remod
elling or even degeneration of the tissue whereto they are
secreted by CL. This up-regulation might be a consequence of
repeated mild ischemia/reperfusion postulated for glaucoma
patients. However, the question as to whether or not there is a
correlation between an increased MMPs activity and glauco-
ma severity should be further clarified. Recently performed
comparative gene transcription profiling in trabecular mesh-
a
b
Fig. 5 a. Principle of “gene hunting” by the “Subtractive Hybridisation”
[1, 34]. Each mRNA-pool consists of individual gene transcripts, which
undergo a comparison by hybridisation of identical (complementary)
parts. The subtraction results in identification of non-complementary
transcripts differentially expressed in two pools of comparison; the
technology enables a consideration of both qualitative (present or
absent) and quantitative (amount of copies per unit weight of mRNA in
the corresponding pool) differences b. Consequent quantification of the
target transcripts (mRNA “Dot-Blot”-analysis), further provided a
strong indication for increased stress, apoptosis, protein damage and
axonal damage as well as insufficient DNA-repair and altered drug-
sensitivity in patients with glaucoma compared to the control group
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work isolated from post-mortem glaucomatous eyes revealed
a significant up-regulation of several cell adhesion molecules
including platelet endothelial cells adhesion molecule-1 and
P-selectin [39]. An enhanced deposition of the cell aggrega-
tion protein cochlin in trabecular meshwork and Schlemm’s
canal of glaucomatous eye supports the crucial role of cellular
adhesion in glaucoma pathology and favours cell adhesion
molecules as potential disease biomarkers [40].
Transcription regulation
Dramatically altered transcription patterns in glaucoma
were reported by several research groups [1, 30, 32, 38].
A reason for this extensive shift in transcription regulation
was unclear for a very long time till a significant up-
regulation of the basic transcriptional regulator AP-2ß was
attributed to glaucoma pathology: AP-2ß has been identified
in CL using the smart technology of disease proteomics
[30]. Protein mapping is demonstrated in Fig. 4a. AP-2
proteins play a decisive role, particularly in eye morpho-
genesis. While the activation of AP-1 leads to an increased
stromelysin (metalloproteinase-3) production in trabecular
meshwork in vitro [41, 42], the expression and activity of
AP-2 controls the activity of the gelatinase B (MMP-9)
[43]. In consensus, MMP-9 was demonstrated to be
significantly up-regulated in leucocytes of glaucoma
patients and to play an important role in tissue remodelling
as a part of glaucomatous degeneration [38]. Therefore, the
concerted up-regulation of AP-2ß and MMP-9 in leucocytes
of glaucoma patients has been proposed to be an important
part of the molecular mechanisms in glaucoma pathology
and a reliable biomarker for diagnostic purposes.
Multidrug resistance
An extensive deregulation of ABC-transporters has been
demonstrated in glaucoma pathology [1, 44, 45]. ABC-
transporters (ATP-binding cassette transporter) usually
translocate a wide variety of structurally unrelated lipophilic
compounds being responsible for drug efflux, and therefore,
for multidrug resistance. ABC 1 has been shown to be
stably up-regulated in CL of glaucoma patients [45]. Joyce
et al. demonstrated a crucial role for ABC 1 in protection
against atherosclerosis [46]. An activity of ABC 1 has been
shown to have a regulating effect on endothelial function
and stimulate nitric oxide bioactivity in arterial walls [47].
The up-regulation of ABC1 in CL of glaucoma patients
might indicate the involvement of this gene in chronic
vascular deregulation frequently observed in glaucoma
pathology, and has been suggested as a potential marker
for early diagnostics of glaucoma [45].
Energy metabolism
“Gene hunting” in CL of glaucoma patients revealed down-
regulated transcripts of Na+/K+-ATPase [36]. An identifi-
cation of the subtracted transcripts is demonstrated in
Fig. 2. Further, abnormal sodium handling has been
Table 1 Types of glaucoma-specific molecular alterations that can be potentially used for development of advanced tools for early and predictive
diagnosis [60]
Type of molecule Possible type of alteration Detection technology
Chromosomal DNA, mitochondrial
DNA
1. (Oxidative) damagea - Comet assay
2. Mutationsa - Disease genomics
3. Polymorphisma - PCR, Restriction analysis, etc.
4. Methylation status of CpG islandsb - Methylation-specific PCR
mRNA 1. Multiple alterations in expression patternsa - Disease transcriptomics: Subtractive hybridisation,
Expression array, Reverse-Transcriptase-PCR,
Real-Time-PCR, etc.
2. Reduced mRNA editing - Reverse-Transcriptase-PCR
Proteins 1. Multiple alterations in expression patternsa - Disease Proteomics: 2D-PAGE, MALDI-TOF,
Western-blot, etc.
2. Posttranslational modificationa - Western-blot, Activity tests (e.g. Zymography
for gelatinases)
3. Phosphorylation statusa - Activity tests
4. Protein misfoldinga - Activity tests
Metabolites (signalling molecules,
amino acids, plasma hormones, etc.)
Altered profilesa Disease Metabolomics: Comparative blood plasma
metabolites profiling, HPLC, Activity tests, etc.
a Types of molecular alterations reported for glaucoma pathology. b Data indicating this kind of alteration collected in our laboratory, which, however, have
not been published until now
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proposed to be associated with ocular hypertensivity and to
contribute to a progression of the optic nerve damage in
both normal-tension and high-tension glaucoma [48, 49].
Na+/K+-ATPase is known to be down-regulated in lympho-
cytes of patients with acute myocardial infarction [50], and
may be one of the reasons for ventricular arrhythmias and
coronary artery spasms. A decrease in intracellular potas-
sium concentration and an increase in intracellular calcium
concentration may play a major role in the pathomechanism
of coronary artery spasms. Inhibition of Na+/K+-ATPase is
one of functional consequences of oxidative membrane
damage caused by an increased oxidative stress [51], which
is triggered e.g. under ischemia/reperfusion. This affects
central thermogenic mechanisms, since Na+/K+-ATPase has
been shown to play a key role in cellular energy balance
and thermogenesis [52, 53]. A decreased activity of Na+/
K+-ATPase triggers vasospasm [54]. Being an important
co-factor of cellular ATPases, magnesium can reverse
delayed vasospasm and reduce the extent of acute ischemic
lesions [55]. Magnesium therapy demonstrates beneficial
effects in vasospastic syndrome and glaucoma [9].
Effect of glaucoma medication on the evaluation
of biomarkers
Evaluation of glaucoma biomarkers under treatment con-
ditions is a particular issue in glaucoma research. Indeed, can
we use the markers proposed for diagnostics of untreated
glaucoma also under glaucoma medication? Are there any
reliable markers which can predict the outcome of glaucoma
treatment? There are some studies clearly demonstrating that
glaucoma medication may definitely mask alterations in
crucial biomarkers such as those of the nitric oxide pathway
[56]. Additionally, toxic side effects of anti-glaucoma drugs
on conjunctiva have been reported: histological studies of
conjunctival tissues in patients who underwent a long-term
glaucoma treatment demonstrated an abnormal infiltration
of inflammatory cells. Consequently, an abnormal expression
of inflammatory markers under various anti-glaucomatous
treatments has been shown [57].
Much progress has been achieved in the development of
markers that can potentially predict the outcome of
glaucoma surgery. In the research of Souchier et al., surgery
success was defined as reduced IOP ≤ 15 mm Hg without
any IOP-lowering drugs at 6 months. Conjunctival expres-
sion levels of trefoil factor family 1 (TFF1) and MUC5AC
as well as HLA-DR in leucocytes have been measured [58]
and an increased expression of all three molecular markers
has been proposed as a potential prediction factor for
successful glaucoma surgery. However, the issue of
glaucoma medication markers is a multifarious one and
requires more research effort.
Perspectives for application of most potent
biotechnological tools
High-accuracy proteome maps of human body fluids open
new perspectives for early molecular diagnostics of chronic
disorders. Abundant scientific evidence from disease
proteomics suggests that disease specific protein expression
patterns in blood are indicative of many—if not most—
human disorders, and might be a powerful tool for early
molecular diagnostics of glaucomatous damage. A non-
invasive molecular diagnostic approach based on disease
specific gene expression patterns in CL has been suggested
for glaucoma [59]. The test foresees a precise expression
profiling of selected genes in CL isolated from fresh blood
samples. These genes (gene products) have been proposed
to play a role in glaucoma pathology and belong to following
pathways: an apoptosis, stress response, DNA-repair, tran-
scription regulation, multidrug resistance, tissue remodelling
and degeneration. Currently a clinical application of the test is
under consideration, and a nanotechnology which should
provide a possibly easy and cheap routine application of the
test is under development. Possible types of molecular
alterations that can be considered for predictive glaucoma
diagnosis and corresponding detection technologies are
summarised in Table 1.
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